Disclosed herein is a novel route of synthesis of syn azide epoxide of formu 5 which is used as a common intermdeiate for asymmetric synthesis of HIV protease inhibitors such as Amprenavir Fosamprenavir Saquinavir and formal synthesis of Darunavir and Palinavir obtained by Cobalt- catalyzed hydrolyti kinetic resolution of racemic anti-(2SR 3SR) - 3 -azido - 4 -phenyl - 1 2- epoxybutane (azido-epoxide).

Disclosed herein is a novel route of synthesis of syn azide epoxide of formu 5 which is used as a common intermdeiate for asymmetric synthesis of HIV protease inhibitors such as Amprenavir Fosamprenavir Saquinavir and formal synthesis of Darunavir and Palinavir obtained by Cobalt- catalyzed hydrolyti kinetic resolution of racemic anti-(2SR 3SR) - 3 -azido - 4 -phenyl - 1 2- epoxybutane (azido-epoxide).

Activated haptens useful for generating immunogens to HIV protease inhibitors immunogens useful for producing antibodies to HIV protease inhibitors and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir nelfinavir amprenavir ritonavir a...

Activated haptens useful for generating immunogens to HIV protease inhibitors immunogens useful for producing antibodies to HIV protease inhibitors and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir nelfinavir amprenavir ritonavir a...

Anticuerpo monoclonal específico para el atazanavir que presenta una reactividad cruzada inferior a 1% con saquinavir nelfinavir indinavir amprenavir ritonavir y lopinavir.

The present invention relates to the use of a dioxolane thymine compound according to the chemical structure of Formula (I): where R1 is H an acyl group a C1-C20 alkyl or ether group a phosphate diphosphate triphosphate or phosphodiester group for use in the treatment of HIV infections which exhibit resistance to 3TC and/or AZT. Preferably compounds according to the present invention are combined with at least one anti-HIV agent which inhibits HIV by a mechanism other than through the inhibition...

Activated haptens useful for generating immunogens to HIV protease inhibitors immunogens useful for producing antibodies to HIV protease inhibitors and antibodies and labeled conjugates useful in immunoassays for HIV protease inhibitors.The novel haptens feature an activated functionality at the central non-terminal hydroxyl group common to all HIV protease inhibitors e.g. saquinavir nelfinavir indinavir amprenavir ritonavir and lopinavir.(From US2003100088 A1)

Activated haptens useful for generating immunogens to HIV protease inhibitors immunogens useful for producing antibodies to HIV protease inhibitors and antibodies and labeled conjugates useful in immunoassays for the HIV protease inhibitor saquinavir. The novel haptens feature an activated functionality at the central non-terminal hydroxyl group. Also described are monoclonal antibodies specific for saquinavir having less than 10% cross-reactivity with lopinavir nelfinavir amprenavir ritonavir a...